BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18063594)

  • 1. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
    Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
    Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
    Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
    Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
    Neto-Ferreira R; Novaes Rocha V; da Silva Torres T; Mandarim-de-Lacerda CA; de Carvalho JJ
    Exp Toxicol Pathol; 2011 Jul; 63(5):473-8. PubMed ID: 20537513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.
    Pelat M; Dessy C; Massion P; Desager JP; Feron O; Balligand JL
    Circulation; 2003 May; 107(19):2480-6. PubMed ID: 12719275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
    Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
    Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
    Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
    Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice.
    Li W; Asagami T; Matsushita H; Lee KH; Tsao PS
    J Pharmacol Exp Ther; 2005 May; 313(2):557-62. PubMed ID: 15665143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
    Coban E; Afacan B
    Platelets; 2008 Mar; 19(2):111-4. PubMed ID: 17852772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
    Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
    J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
    Gelosa P; Ballerio R; Banfi C; Nobili E; Gianella A; Pignieri A; Brioschi M; Guerrini U; Castiglioni L; Blanc-Guillemaud V; Lerond L; Tremoli E; Sironi L
    J Pharmacol Exp Ther; 2010 Jul; 334(1):199-205. PubMed ID: 20332187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
    Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
    J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
    Landsberger M; Jantzen F; Könemann S; Felix SB
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
    Liuni A; Luca MC; Gori T; Parker JD
    J Am Coll Cardiol; 2010 Mar; 55(10):1002-6. PubMed ID: 20202516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
    Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
    Loch D; Levick S; Hoey A; Brown L
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
    Famer D; Crisby M
    Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
    Sironi L; Gianazza E; Gelosa P; Guerrini U; Nobili E; Gianella A; Cremonesi B; Paoletti R; Tremoli E
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):598-603. PubMed ID: 15681303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
    Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
    Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
    Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
    J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.